Xeris Pharmaceuticals has announced positive findings from the outpatient stage of a Phase 2 proof-of-concept study of its developmental ready-to-use (RTU) glucagon in patients who experience postprandial hypoglycaemic episodes following bariatric surgery.

Researchers from the University of British Columbia, Canada, believe they have identified a gene that may prevent weight gain, after using a genetic database of more than 47,000 people in Estonia.